In a large, single-centre cohort study, two-thirds of patients with acute ischemic stroke had one or more undiagnosed major vascular risk factors, most notably dyslipidemia, hypertension, and atrial fibrillation (AF). Patients with undiagnosed risk factors were relatively young, were more often women, and had more often a patent foramen ovale (PFO).
A retrospective analysis, performed by Dr André Rêgo (Lausanne University Hospital and University of Lausanne, Switzerland), included 4,354 patients from the ASTRAL registry from 2003–2018, who had been admitted within 24 hours after a stroke [1]. Their median age was 70 years (IQR 15.2) and 44.7% were women.
1,125 patients (25.8%) were unaware of having any major risk factor; mean age in this subgroup was 59 years, as opposed to 74 years in the group with diagnosed risk factors. Within this group, 341 (30.3%) indeed had no undiagnosed major risk factor(s), but 784 (67.7%) did have at least one. Of these, 61.4% had newly detected dyslipidemia, 23.7% had hypertension, 10.2% had AF, 5.2% had diabetes, 2.0% had ejection fraction <35%, and 1.0% had coronary disease. “The results, however, may not be generalisable to other countries, since Switzerland is known for its high-quality healthcare system, high general level of education, and relatively healthy population. If we did this study in another context, we probably would see even more undiagnosed risk factors,” said Dr Rêgo.
Having a major stroke risk factor without being aware of it was associated with lower age, non-Caucasian ethnicity, PFO, contraceptive use, and smoking (in patients ≥55 years old). Also found were negative associations with antiplatelet use before event and a higher BMI. In this group, there was a higher frequency of PFO-related strokes and a lower frequency for large vessel, lacunar, cardiac, or multiple coexisting causes.
Improving the detection of undiagnosed risk factors would require a shift in healthcare focus, according to Dr Rêgo. “We still have a healthcare system excessively directed toward acute disease and less to chronic diseases and preventive medicine.”
- Rêgo A, et al. Undiagnosed major risk factors in patients with acute ischaemic stroke: clinical profile, stroke mechanisms and outcome. EAN 2022, EOP-261, EAN 2022, 25–28 April, Vienna, Austria.
Copyright ©2022 Medicom Medical Publishers
Posted on
« Absence of Susceptibility Vessel Sign points to malignancy in stroke patients Next Article
Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy »
Table of Contents: EAN 2022
Featured articles
Letter from the Editor
Overarching Theme
Migraine
Targeting cortical activation by transcranial magnetic stimulation
Erenumab more than doubles plasma CGRP levels
Over a third of patients responds late to CGRP antibodies
Multiple Sclerosis
When to start, switch, and stop MS therapy: Real-world evidence counts
Updated EAN-ECTRIMS guideline on pharmacological MS treatment
Gut microbiota composition associated with disability worsening
Teriflunomide in children with MS: final results of TERIKIDS
Estimating brain age in MS: machine learning versus deep learning
Ofatumumab improves cognitive processing speed
Parkinson’s Disease
Intestinal alterations in patients with Parkinson’s disease
Gene variants impact survival in monogenic Parkinson’s disease
Cerebrovascular Disease and Stroke
Most acute stroke patients have undiagnosed risk factors
Absence of Susceptibility Vessel Sign points to malignancy in stroke patients
Acute stroke management: from time window to tissue window?
Epilepsy
Seizure forecasting with non- and minimally-invasive devices
Real-world efficacy of cenobamate in focal-onset seizures
Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy
COVID-19
COVID-19 elevates risk of neurodegenerative disorders
More headaches in adolescents during COVID-19 pandemic
AstraZeneca vaccination and risk of cerebral venous sinus thrombosis
Large impact of COVID-19 on dementia diagnosis and care
Miscellaneous
Tau autoimmunity associated with systemic disease
Long-term effects of avalglucosidase alfa in late-onset Pompe disease
European survey of patient satisfaction in the treatment of cancer-related neuropathic pain
Related Articles
Tau autoimmunity associated with systemic disease
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy